Long-acting injectable antipsychotics and their use in court-ordered treatment: A cross-sectional survey of psychiatric pharmacists' perceptions

Abstract

Introduction People with serious mental illness may be subjected to “court-ordered treatment” (COT), per the mental health statutes of their respective state. COT enforces adherence to a psychiatric treatment regimen and may involve involuntary medication administration. Long-acting injectable (LAI) antipsychotics are frequently used in this setting, although little is known about the clinical effectiveness or patterns of use of these agents in the context of COT. Because psychiatric pharmacists are medication experts, we sought to characterize their perceptions and experiences on this topic. Methods A cross-sectional, electronic, 14-item survey was administered via the College of Psychiatric and Neurologic Pharmacists listserv from October 9, 2018, to November 9, 2018. The survey collected demographic information, experience and use of LAI antipsychotics at each practice site, and perception of LAI antipsychotics. Results Of 843 possible respondents, 72 completed the survey, yielding an 8.5% response rate. LAIs were perceived as underused or adequately used as a whole, with a significant difference in perception favoring the opinion that LAIs are underused versus overused for those respondents who perceived an adherence benefit (P = .042). We also found that LAIs were used disproportionately in the context of COT versus oral formulations (P = .03). Discussion The use of LAIs in the context of COT has not been studied, and it may expose this vulnerable population to adverse effects from medications they are legally compelled to take. Further research on the perceptions of other interdisciplinary team members and the clinical impact of LAI use in COT is needed.

Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders

“…Although caution should be exercised when extrapolating results from this French population to other countries, the validity of the study findings is underscored by the fact that patients were drawn from a nationwide population (i.e., without selection bias) and were analyzed according to a pre-specified protocol. LAIs are frequently prescribed when patients are involuntarily committed to treatment by court order [ 41 ]. Within the framework of involuntary commitment, the patient must take her/his treatment and attend her/his follow-up appointments, without which he/she may be quickly re-hospitalized.…”

Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution

“…The toxicity of neuroleptics stems from their interactions with the following receptors: dopamine (extrapyramidal symptoms), α 1 -adrenergic (orthostatic hypotension, reflex tachycardia), muscarinic (anticholinergic symptoms), and histaminic receptors (sedation) [ 28 , 29 ]. Symptoms of neuroleptic overdose can be overcome using diphenhydramine or benzatropine.…”

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use

“…It is unknown how many patients receiving LAIAs are receiving them as part of a court order. Practices and statutes regarding court-ordered medication treatment vary between states 24 and even between community mental health centers. Evidence 25 suggests patients receiving medications under a court order perceive a higher degree of coercion which may negatively affect the ability to develop a therapeutic alliance.…”